Add BrightSurf on Google Email

COVID-19 can trigger self-attacking antibodies

Researchers found that people infected with COVID-19 develop a wide variety of autoantibodies up to six months after recovery, and these autoantibodies persist over time. The study suggests that understanding these autoantibody responses could help identify ways to treat and prevent long-term symptoms.

SourceCedars-Sinai Medical Center·JournalJournal of Translational Medicine·DateDec 29, 2021

The Lancet: Phase 3 trial reports one dose of Ad5-nCoV COVID-19 vaccine is safe and effective, including against severe disease

A phase 3 trial has shown that one dose of the Ad5-nCoV COVID-19 vaccine is highly effective against severe disease, with an efficacy rate of 91.7% at 28 days post-vaccination. The vaccine has also been found to be safe, with no serious vaccine-related adverse events or deaths reported among trial participants.

SourceThe Lancet·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateDec 23, 2021

The role of trust and knowledge in overcoming vaccination hesitancy

A study published in PNAS found that trust and knowledge about vaccination are stronger predictors of vaccination than Covid-specific factors. Background beliefs and behavior regarding vaccination in general were more than twice as predictive of the change in vaccination as beliefs about the pandemic itself.

SourceAnnenberg Public Policy Center of the University of Pennsylvania·JournalProceedings of the National Academy of Sciences·TypeSurvey·DateDec 22, 2021

COVID-19–vaccinated kidney transplant recipients are especially vulnerable to emerging SARS-CoV-2 variants

New research reveals that COVID-19 vaccinated kidney transplant recipients have impaired antibody responses against emerging SARS-CoV-2 variants, including B.1.351 and B.1.617.2. The study found that these patients require additional vaccinations to maintain high levels of neutralizing antibodies.

SourceAmerican Society of Nephrology·JournalClinical Journal of the American Society of Nephrology·DateDec 22, 2021

Study compares COVID-19 vaccines’ ability to stimulate immune protection against the coronavirus

The study found that two doses of Moderna and Pfizer vaccines produced higher antibody concentrations than a single dose of Johnson & Johnson vaccine, with levels more than 10 times higher for recovered COVID-19 patients. The analysis also showed that the Moderna vaccine had the lowest risk for breakthrough infections.

SourceMassachusetts General Hospital·JournalThe Journal of Infectious Diseases·TypeObservational study·DateDec 20, 2021

mRNA vaccines highly effective at preventing death from COVID-19, less effective at preventing infection

Researchers found that mRNA vaccines were highly effective (86%) in preventing SARS-CoV-2-related deaths among vaccinated individuals, especially in the elderly population. However, vaccine effectiveness against infection was lower (69%) and decreased with increasing age and comorbidity burden.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeRandomized controlled/clinical trial·DateDec 20, 2021

Cough or fever first? Study analyzes order of COVID-19 symptoms

A new study published in PLOS Computational Biology found that the order of COVID-19 symptoms varies depending on the SARS-CoV-2 variant. In the USA, cough was most likely to be the first symptom, while fever and diarrhea were more common third symptoms.

SourcePLOS·JournalPLOS Computational Biology·TypeComputational simulation/modeling·DateDec 16, 2021

Series of preclinical studies supports the Army’s pan-coronavirus vaccine development strategy

Recent preclinical study results demonstrate the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by WRAIR elicits potent immune responses and offers broad protection against SARS-CoV-2 variants and other coronaviruses. The SpFN vaccine uses a ferritin platform to present multiple copies of the coronavirus spike protein, i...

SourceThe U.S. Military HIV Research Program (MHRP)·JournalScience·TypeRandomized controlled/clinical trial·DateDec 16, 2021

Omicron may cause 100,000 cancelled operations in England this winter

A new study warns that Omicron could lead to 100,273 fewer elective operations performed over the three winter months due to increased hospital admissions and COVID-19 patients. The model used NHS England data from September 2020 to July 2021 to project elective surgery activity based on the number of COVID-19 patients in hospital.

SourceUniversity of Birmingham·JournalThe Lancet·TypeData/statistical analysis·DateDec 16, 2021

Shark antibody-like proteins neutralize COVID-19 virus, help prepare for future coronaviruses

Researchers have discovered unique antibody-like proteins from sharks that can prevent the COVID-19 virus and its variants from infecting human cells. These shark-derived protein 'VNARs' are a promising new tool in the fight against SARS-CoV-2, with potential applications for future coronavirus outbreaks.

SourceUniversity of Wisconsin-Madison·JournalNature Communications·TypeExperimental study·DateDec 16, 2021

Respiratory discovery could improve survival of COVID-19 intensive care patients

A clinical trial has revealed that COVID-19 patients on ventilators have less surfactant in their lungs due to the virus. The researchers suggest that giving extra surfactant for a longer period could help save lives by supporting breathing and allowing lung cells to repair after the infection passes.

SourceUniversity of Southampton·JournalAmerican Journal of Respiratory and Critical Care Medicine·TypeRandomized controlled/clinical trial·DateDec 14, 2021

Overweight children are developing heart complications

A new study from the University of Georgia found that overweight youth are developing signs of artery stiffness, a significant risk factor for cardiovascular disease. Researchers measured visceral fat levels and arterial stiffness in over 600 children, adolescents, and young adults, revealing higher levels of visceral fat and arterial ...

SourceUniversity of Georgia·JournalPediatric Obesity·DateDec 14, 2021

Researchers at Aarhus University, Denmark, develop a molecule that blocks SARS-CoV-2 infection

A research team at Aarhus University has developed an RNA aptamer that attaches to the surface of SARS-CoV-2 virus particles, preventing it from entering human cells. This molecule is cheaper and easier to manufacture than current antibodies, making it a promising tool for detecting covid-19 infection.

SourceAarhus University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateDec 13, 2021

A longer-lasting COVID vaccine? UCLA study points the way

Researchers at UCLA have identified rare T cells capable of targeting a protein found in SARS-CoV-2 and other coronaviruses. By adding a fragment of this protein to vaccines, they hope to create a longer-lasting immune response and increase protection against new variants. This breakthrough could lead to more effective COVID-19 vaccines.

SourceUniversity of California - Los Angeles Health Sciences·JournalCell Reports·TypeExperimental study·DateDec 10, 2021

Violence increased most in marginalized neighborhoods early in the COVID-19 pandemic

A new UC Davis study tracks firearm violence, assault, and homicide in 13 major US cities by zip code, revealing stark disparities. Firearm violence increased 29.3%, homicides by 27.7%, while robberies decreased 23.3% and rapes by 31.4% during the first five months of the pandemic.

SourceUniversity of California - Davis Health·JournalAmerican Journal of Public Health·TypeData/statistical analysis·DateDec 9, 2021

Novel computer simulation method can accelerate COVID-19 drug discovery

Researchers developed a novel computer simulation method that can analyze key proteins in the reproductive cycle of SARS-CoV-2, promising to accelerate the search for bioactive compounds against COVID-19. The method estimates a reduction in research time from two to three years to under a year.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Biomolecular Structure and Dynamics·DateDec 8, 2021